Skip to content

News

In the Spring of 2020, four of Asarina Pharma’s seven test centers in its randomized, placebo-controlled Phase IIa menstrual migraine study had to...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE 95% of patients have been recruited in our Phase IIa proof-of-concept study. In total since...
FINANCIAL HIGHLIGHTS SIGNIFICANT EVENTS DURING THE FIRST QUARTER PMDD In April 2020 we released inconclusive topline results from our phase IIb study in...
Dividend In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019. Discharge from liability...
“Obviously, we had hoped for a different outcome" says Peter Nordkild, CEO of Asarina Pharma. “To all women living with PMDD I can only...
For further information see the attached, plus please visit https://asarinapharma.com/investors/financial-reports/ For further information, please contact...
The Company is closely monitoring the development of covid-19, the corona virus, and will revert with more information closer to the AGM if it is deemed...
Asarina Pharma’s Phase IIb study into PMDD (premenstrual dysphoric disorder) was conducted in the UK, Germany, Poland and Sweden. Enrolment was completed...
The event is scheduled for 14.00-16.00 on March 26 at: https://financialhearings.com/event/12815 Please register at: https://financialhearings.com/event/12602/register/live_event...
Date: March 26, 2020 Time: 14.00-17.00, registration from 13.30 Location: Helio GT30, Grev Turegatan 30, Stockholm With presentations from PMDD practitioners...